Accès gratuit
Numéro
Réanimation
Volume 24, Numéro 5, Septembre 2015
Neurologie-urgences
Page(s) 527 - 541
Section Update / Mise Au Point
DOI https://doi.org/10.1007/s13546-015-1104-4
Publié en ligne 30 juillet 2015
  • Auwarter V, Kristensen PK, Bartels EM, et al (2009) “Spice” and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–7 [CrossRef] [PubMed] [Google Scholar]
  • Dargan PI, Wood DM (2013) Novel psychoactive substances. Classification, pharmacology and toxicology. Elsevier Inc, San Diego [Google Scholar]
  • EMCDDA 2015: European Monitoring Centre for Drugs and Drug Addiction. Perspectives on Drugs – the synthetic cannabinoids. Available at http://www.emcdda.europa.eu/attachements.cfm/att_212361_EN_EMCDDA_POD_2013_Synthetic%20cannabinoids.pdf Last accessed 3rd July 2015 [Google Scholar]
  • Christensen R, Kristensen PK, Bartels EM, et al (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706–13 [CrossRef] [PubMed] [Google Scholar]
  • Dargan PI, Hudson S, Ramsey J, Wood DM (2011) The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in “Spice”. Int J Drug Policy 22:274–7 [CrossRef] [PubMed] [Google Scholar]
  • EMCDDA 2014: EMCDDA-Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA. Available at: http://www.emcdda.europa.eu/attachements.cfm/att_240380_EN_TDAN15001ENN.pdf Last accessed 3rd July 2015 [Google Scholar]
  • UNODC (2014): United Nations Office on Drugs and Crime. Global Synthetic Drugs Assessment Amphetamine-type stimulants and new psychoactive substances. Available at: https://www.unodc.org/documents/scientific/2014_Global_Synthetic_Drugs_Assessment_web.pdf Last accessed 3rd July 2015 [Google Scholar]
  • UNODC 2011: United Nations Office on Drugs and Crime. Synthetic cannabinoids in herbal products. Available at: https://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf Last accessed 3rd July 2015 [Google Scholar]
  • Brown K (2011) New Zealand bans synthetic cannabinoids BMJ 343:5395 [CrossRef] [Google Scholar]
  • Therapeutic Goods Administration 2012. Final decision and reasons for decisions by delegates of the secretary to the department of health and ageing. Commonwealth of Australia. Canberra [Google Scholar]
  • ACMD 2009: Advisory council on the misuse of drugs 2009. Consideration of the major cannabinoid agonists. Home Office. London [Google Scholar]
  • ACMD 2012: Advisory Council on the Misuse of Drugs. Further consideration of the synthetic cannabinoids. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119042/synthetic-cannabinoids-2012.pdf Last accessed 3rd July 2015 [Google Scholar]
  • ACMD 2014: Advisory Council on the Misuse of Drugs. Third generation synthetic cannabinoids. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/380161/CannabinoidsReport.pdf Last accessed 3rd July 2015 [Google Scholar]
  • Fattore L, Fratta W (2011) Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5:60 [CrossRef] [PubMed] [Google Scholar]
  • Hammersley R (2010) Dangers of banning spice and the synthetic cannabinoid agonists. Addiction 105:373 [PubMed] [Google Scholar]
  • Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Progr Neuro Psychopharm Biol Psych 39:234–43 [CrossRef] [Google Scholar]
  • Zuurman L, Passier PC, de Kam MI, et al (2009) Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers. J Psychopharmacol 23:633–44 [CrossRef] [PubMed] [Google Scholar]
  • Martin BR, Wiley JL, Beletskaya I, et al (2006) Pharmacological characterization of novel water-soluble cannabinoids. J Pharmacol Exp Ther 318:1230–9 [CrossRef] [PubMed] [Google Scholar]
  • Seely KA, Patton AL, Moran CI, et al (2013) Forensic investigation of K2, Spice, and “bath salt” commercial preparations: A three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. For Sci Int 233:416–22 [Google Scholar]
  • Hudson S, Ramsey J, King L, et al (2010) Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in “herbal high” products. J Anal Toxicol 34:252–60 [CrossRef] [PubMed] [Google Scholar]
  • Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108:534–44 [CrossRef] [PubMed] [Google Scholar]
  • Teske J, Weller JP, Fieguth A, et al (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalene-1-yl-(1-pen-tylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:2659–63 [CrossRef] [PubMed] [Google Scholar]
  • Grigoryev AJ, Kavanagh P, Melnik A (2013) The detection of the urinary metabolites of 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone (AM-694), a high affinity cannabimimetic, by gas chromatography — mass spectrometry. Drug Test Anal 5:110–5 [CrossRef] [PubMed] [Google Scholar]
  • Kneisel S, Teske J, Auwarter V (2014) Analysis of synthetic cannabinoids in abstinence control: long drug detection windows in serum and implications for practitioners. Drug Test Anal 6:135–6 [CrossRef] [PubMed] [Google Scholar]
  • Winstock AR, Barratt MJ (2013) Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 131:106–11 [CrossRef] [PubMed] [Google Scholar]
  • Tofighi B, Lee JD (2012) Internet highs — seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 6:240–1 [CrossRef] [PubMed] [Google Scholar]
  • Barratt MJ, Cakic V, Lenton S (2013) Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 32:141–6 [CrossRef] [PubMed] [Google Scholar]
  • Vandrey R, Dunn KE, Fry JA, Girling ER (2012) A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 120:238–41 [CrossRef] [PubMed] [Google Scholar]
  • Hoyte CO, Jacob J, Monte AA, et al (2012) A characterization of synthetic cannabinoid exposures reported to the national poison data system in 2010. Ann Emerg Med 60:435–8 [CrossRef] [PubMed] [Google Scholar]
  • Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL (2014) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: Mechanisn underlying greater toxicity? Life Sci 97:45–54 [CrossRef] [PubMed] [Google Scholar]
  • Paine MF, Hart HL, Ludington SS, et al (2006) The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–6 [CrossRef] [PubMed] [Google Scholar]
  • Chimalakonda KC, Seely KA, Bratton SM, et al (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Distrib 40:2174–84 [CrossRef] [Google Scholar]
  • Wohlfarth A, Scheidweiler KB, Chen X, et al (2013) Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem 85:3730–8 [CrossRef] [PubMed] [Google Scholar]
  • Chimalakonda KC, Bratton SM, Le VH, et al (2011) Conjugation of synthetic cannabinoids JWH-018 and JWH 073, metabolites by human UDP-glucuronosyltransfers. Drug Metab Dispos 39:1967–76 [CrossRef] [PubMed] [Google Scholar]
  • Grigoryev AJ, Kavanagh P, Melnik A (2012) The detection of the urinary metabolites of 3-[(adamanan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal 4:519–24 [CrossRef] [PubMed] [Google Scholar]
  • Kavanagh P, Grigoryev A, Melnik A, et al (2013) Detection and tentative identification of urinary phase 1 metabolites of phenylacetylindole cannabimimetics JWH-203 and JWH-251, by GC-MS and LC-MS/MS. J Chromatogr V Analyt Technol Biomed Life Sci 934:102–8 [CrossRef] [Google Scholar]
  • Mascia MS, Obinu MC, Ledent C, et al (1999) Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mics. Eur J Pharmacol 383(3):R1–R2 [CrossRef] [PubMed] [Google Scholar]
  • Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58:315–48 [CrossRef] [PubMed] [Google Scholar]
  • Matsuda LA, Lolait SJ, Brownstein MJ, et al (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561–4 [CrossRef] [PubMed] [Google Scholar]
  • Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–5 [CrossRef] [PubMed] [Google Scholar]
  • Hajos N, Freund TF (2002) Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121:73–82 [CrossRef] [PubMed] [Google Scholar]
  • Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH-018, a common constituent of “Spice” herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585–93 [CrossRef] [PubMed] [Google Scholar]
  • Atwood BK, Lee D, Straiker J, et al (2011) CP47, 497-C8 and JWH-073 commonly found in “Spice” herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659:139–45 [CrossRef] [PubMed] [Google Scholar]
  • Howlet AC, Barth F, Bonner TI, et al (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–202 [CrossRef] [PubMed] [Google Scholar]
  • Nakajima J, Takahashi M, Seto T, et al (2011) Identification and quantification of two benzoylindoled AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl) methadone, and three cannabimimetic naphthoylindoles JWH-210, JWH 122, and JWH-019 as adulterants in illegal products obtained via the Internet. Forensic Toxicol 29:95–110 [CrossRef] [Google Scholar]
  • Paronis CA, Nikas SP, Shukla VG, Makriyannis A (2012) Delta(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol 23:802–5 [CrossRef] [PubMed] [Google Scholar]
  • Blunt D (2012) Drug misuse declared: findings from the 2011/12 crime survey for England and Wales 2nd edition [Google Scholar]
  • Smith K, Flatley J (2011) Drug misuse declared: findings from the 2010/11 British Crime Survey Home Office Statistical Bulletin [Google Scholar]
  • Pabst A, Piontek D, Kraus L, Muller S (2010) Substance use and substance use disorders results of the 2009 epidemiology survey of substance abuse. Sucht 56:327–36 [CrossRef] [Google Scholar]
  • Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE (2013) Monitoring the future national results on drug use: 2012 overview, key findings on adolescent drug use. Institute for Social Research, The University of Michigan, Ann Arbor [Google Scholar]
  • Werse B, Muller O, Schell C, Morgenstern C (2011) Annual Report “MoSyD”. Drug trends in Frankfurt am Main 2010. Goethe-University Frankfurt am Main, Centre for Drug Research. [Google Scholar]
  • Hu X, Primack BA, Barnett TE, Cook RL (2011) College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 6:16 [CrossRef] [PubMed] [Google Scholar]
  • Berry-Caban CS, Kleinschmidt PE, Rao DS, Jenkins K (2012) Synthetic cannabinoid and cathinone use among US soldiers. US Army Med Dep J 19–24 [PubMed] [Google Scholar]
  • Monitoring the future: a continuing study of American youth. (online) Available: http://monitoringthefuture.org/ Last accessed 3rd July 2015 [Google Scholar]
  • STUDES 2012: Spanish Observatory on Drugs (2012). Survey on drug use amongst Secondary School Students in Spain. Available at: http://www.pnsd.msc.es/Categoria2/observa/pdf/8_ESTUDES_2012_Informe.pdf Last accessed 3rd July 2015 [Google Scholar]
  • Johnson JD, O’Malley PM, Bachman JG, Schulenberg JE (2012) Monitoring the future national survey results on drug use, 1975–2011: vol I, Secondary school students. Institute for Social Research, The University of Michigan, Ann Arbor [Google Scholar]
  • Winstock A (2011) The 2011 drug surveys. MixMag 238:50–9 [Google Scholar]
  • Winstock A (2012) MixMag/Global drugs surveys. MixMag 251:68–73 [Google Scholar]
  • Winstock AR, Barratt MJ (2013) The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol Clin Exp 28:390–3 [CrossRef] [Google Scholar]
  • Wood DM, Hunter L, Measham F, Dargan PI (2012) Limited use of novel psychoactive substances in South London nightclubs. QJM 105:959–64 [CrossRef] [PubMed] [Google Scholar]
  • Hestley R, Shelby MK, Crouch DJ, et al (2012) Prevalence of synthetic cannabinoids in US athletes: initial findings. J Anal Toxicol 36:588–93 [CrossRef] [PubMed] [Google Scholar]
  • Kronstrand R, Roman M, Andersson M, Eklund A (2013) Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 37:534–41 [CrossRef] [PubMed] [Google Scholar]
  • Castellanos D, Singh S, Thornton G, et al (2011) Synthetic cannabinoid use: a case series of adolescents. J Adolesc Health 49:347–9 [CrossRef] [PubMed] [Google Scholar]
  • Hurst D, Loeffler G, McLay R (2011) Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry 168:1119 [CrossRef] [PubMed] [Google Scholar]
  • Werse B, Morgenstern C (2011) Final report-online-survey on ‘legal highs’ (German). Goeth-University Frankfurt am Main, Centre for Drug Research [Google Scholar]
  • Wood DM, Dargan PI (2012) Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit 34:363–7 [CrossRef] [PubMed] [Google Scholar]
  • Forrester MB, Kleinschmidt K, Schwarz E, Young A (2012) Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol 31:1006–11 [CrossRef] [PubMed] [Google Scholar]
  • Helander A, Beck O, Hagerkvist R, Hulten P (2013) Identification of novel psychoactive drug use in Sweden based on laboratory analysis — initial experiences from the STRIDA project. Scan J Clin Lab Invest 73:400–6 [CrossRef] [Google Scholar]
  • Simmons J, Cookman L, Kang C, Skinner C (2011) Three cases of “spice” exposure. Clin Toxicol 49:431–3 [CrossRef] [PubMed] [Google Scholar]
  • Monte AA, Bronstein AC, Heard KJ, Iwanicki JL (2014) An outbreak of exposure to a novel synthetic cannabinoid. NEJM 370:389–90 [CrossRef] [Google Scholar]
  • Schneir AB, Cullen J, Ly BT (2011) “Spice girls”: Synthetic cannabinoid intoxication. J Emerg Med 40:296–9 [CrossRef] [PubMed] [Google Scholar]
  • Hillebrand J, Olszewski D, Sedefov R (2010) Legal highs on the Internet. Subst Use Misuse 45:330–40 [CrossRef] [PubMed] [Google Scholar]
  • Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108:534–44 [CrossRef] [PubMed] [Google Scholar]
  • Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90:45–60 [CrossRef] [PubMed] [Google Scholar]
  • Harris CR, Brown A (2013) Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 44:360–6 [CrossRef] [PubMed] [Google Scholar]
  • Lapoint J, James LP, Moran CL, et al (2011) Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 49:760–4 [CrossRef] [PubMed] [Google Scholar]
  • Freeman MJ, Rose DZ, Myers MA, et al (2013) Ischaemic stroke after use of the synthetic marijuana “spice”. Neurology 81:2090–3 [CrossRef] [PubMed] [Google Scholar]
  • Berson-Leung ME, Yeung LY, Kumar S (2014) Synthetic cannabis and acute ischaemic stroke. J Stroke Cerebrovasc Dis 23:1239–41 [CrossRef] [PubMed] [Google Scholar]
  • Takematsu M, Hoffman RS, Nelson LS, et al (2014). A case of acute cerebral ischaemia following inhalation of a synthetic cannabinoid. Cin Toxicol 52:973–5 [CrossRef] [Google Scholar]
  • Mir A, Obafemi A, Young A, Kane C (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128:1622–7 [CrossRef] [PubMed] [Google Scholar]
  • McKeever RG, Vearrier D, Jacobs D, et al (2015) K2 — not the spice of life — synthetic cannabinoids and ST elevation MI. J Med Toxicol 11:129–131 [CrossRef] [PubMed] [Google Scholar]
  • McQuade D, Hudosn S, Dargan PI, Wood DM (2013) First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 69:373–6 [CrossRef] [PubMed] [Google Scholar]
  • Pant S, Deshmukh A, Dholaria B, et al (2012) Spicy Seizure. Am J Med Sci 344:67–8 [CrossRef] [PubMed] [Google Scholar]
  • Bhanushali GK, Jain G, Fatima H, et al (2013) AKI associated with synthetic cannabinoids: a case series. Clin Kidney J 6:330–3 [CrossRef] [PubMed] [Google Scholar]
  • Kazory A, Aiyer R (2013) Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney 6:330–3 [CrossRef] [PubMed] [Google Scholar]
  • Every-Palmer S (2011) Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 117:152–7 [CrossRef] [PubMed] [Google Scholar]
  • Faircloth J, Khandheria B (2012) Case report: adverse reaction to synthetic marijuana. Am J Addict 21:289–90 [CrossRef] [PubMed] [Google Scholar]
  • Muller H, Huttner HB, Kohrmann M, et al (2010) Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 42:152–3 [CrossRef] [Google Scholar]
  • Bebarta VS, Ramirez S, Varney SM (2012) Spice: a new “legal” herbal mixture abused by young active duty military personnel. Substance Abuse 33:191–4 [CrossRef] [PubMed] [Google Scholar]
  • Cohen J, Morrison S, Greenberg J, Saidinejad M (2012) Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 129:e1064–e7 [CrossRef] [PubMed] [Google Scholar]
  • Young AC, Schwarz E, Medina G, et al (2012) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 30:1320 [CrossRef] [Google Scholar]
  • Obafemi AI, Kleinschmidt K, Goto C, Fout D (2015) Cluster of acute toxicity from ingestion of synthetic cannabinoid-laced brownies. J Med Toxicol [in press] [Google Scholar]
  • Westerbergh J, Hulten P (2011) Novel synthetic cannabinoids, CRA13, JWH-015, JWH-081 and JWH-210 — detected in a case series. Clin Tox 49:222 [Google Scholar]
  • Drenzek C, Geller RJ, Steck A, et al (2013) Notes from the field: severe illness associated with synthetic cannabinoid use — Brunswick, Georgia. MMWR 62:939 [Google Scholar]
  • Schwartz MD, Trecki J, Edison LA, et al (2015) A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med 48:573–80 [CrossRef] [PubMed] [Google Scholar]
  • Centers for Disease Control and Prevention (CDC) (2012) Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Rep 62:93–8 [Google Scholar]
  • Thornton SL, Wood C, Friesen MW, Gerona RR (2013) Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol 51:189–90 [CrossRef] [PubMed] [Google Scholar]
  • Buser GL, Gerona RR, Horowitz BZ, et al (2014) Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol 52:664–73 [CrossRef] [PubMed] [Google Scholar]
  • Alhadi S, Tiwari A, Vohra R, et al (2013) High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 9:199–206 [CrossRef] [PubMed] [Google Scholar]
  • Berkowitz EA, Henry TS, Veeraraghavan S, et al (2015) Pulmonary effects of synthetic marijuana: chest radiography and CT findings. AJR 204:750–7 [CrossRef] [Google Scholar]
  • Oluwabusi OO, Lobach L, Akhtar U, et al (2012) Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol 22:393–5 [CrossRef] [PubMed] [Google Scholar]
  • Glue P, Al-Shaqsi S, Hancock D, et al (2013) Hospitalisation associated with use of the synthetic cannabinoid K2. NZ Med J 126:18–23 [Google Scholar]
  • Ginsburg BC, Schulze DR, Hruba L, McMahon LR (2012) JWH-018 and JWH-073: Delta(9)-tetcahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther 340:37–45 [CrossRef] [PubMed] [Google Scholar]
  • Hruba L, Ginsburg BC, McMahon LR (2012) Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by delta(9)-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther 342:843–9 [CrossRef] [PubMed] [Google Scholar]
  • Nacca N, Vatti D, Sullivan R, et al (2013) The synthetic cannabinoid withdrawal syndrome. J Addict Med 7:296–8 [CrossRef] [PubMed] [Google Scholar]
  • Zimmermann US, Winkelmann PR, Pilhatsch M, et al (2009) Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Arztebl Int 106:464–7 [PubMed] [Google Scholar]
  • Rominger A, Cumming P, Xiong G, et al (2013) Effects of acute detoxification of the herbal blend “spice gold” on dopamine D receptor availability: A (F)fallypride PET study. Eur Neuropsychopharmacol 23:1606–10 [CrossRef] [PubMed] [Google Scholar]
  • Patton AL, Chimalakonda KC, Moran CL, et al (2013) K2 toxicity: Fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 58:1676–80 [CrossRef] [PubMed] [Google Scholar]
  • Bottei E (2014) First report of drug concentrations of the synthetic cannabinoid 5F-PB22 found on post-mortem testing. Clin Toxicol (Phila) 52:750 [Google Scholar]
  • Behonick G, Shanks KG, Firchau DJ, et al (2014) Four post-mortem case reports with quantitative detection of the synthetic cannabinoid 5F-PB22. J Anal Toxicol 38:559–62 [CrossRef] [PubMed] [Google Scholar]
  • Shanks KG, Winston D, Heidingsfelder J, Behonick G (2015) Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int 252: e6–e9 [CrossRef] [PubMed] [Google Scholar]
  • Benford DM, Caplan JP (2011) Psychiatric sequelae of Spice, K2, an synthetic cannabinoid receptor agonists. Psychosomatics 52:295 [CrossRef] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.